273 related articles for article (PubMed ID: 17696202)
1. Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency.
Yenson PR; Forrest D; Schmiegelow K; Dalal BI
Am J Hematol; 2008 Jan; 83(1):80-3. PubMed ID: 17696202
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
[TBL] [Abstract][Full Text] [Related]
3. Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine induced myelosuppression.
Leung M; Piatkov I; Rochester C; Boyages SC; Leong RW
Intern Med J; 2009 Feb; 39(2):121-6. PubMed ID: 19356188
[TBL] [Abstract][Full Text] [Related]
4. Thiopurines in Crohn's disease, is there something new?
Miheller P; Lakatos PL
Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1505-14. PubMed ID: 20919963
[TBL] [Abstract][Full Text] [Related]
5. Leukopenia due to parvovirus B19 in a Crohn's disease patient using azathioprine.
van Asseldonk DP; Kanis BM; de Boer NK; van Bodegraven AA
Digestion; 2009; 79(4):211-4. PubMed ID: 19390192
[TBL] [Abstract][Full Text] [Related]
6. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
7. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
[TBL] [Abstract][Full Text] [Related]
8. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
[TBL] [Abstract][Full Text] [Related]
9. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
Banerjee S; Bishop WP
J Pediatr Gastroenterol Nutr; 2006 Sep; 43(3):324-30. PubMed ID: 16954954
[TBL] [Abstract][Full Text] [Related]
10. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?
Sanderson J; Ansari A; Marinaki T; Duley J
Ann Clin Biochem; 2004 Jul; 41(Pt 4):294-302. PubMed ID: 15298741
[TBL] [Abstract][Full Text] [Related]
11. Fatal myelotoxicity after azathioprine treatment.
Slanar O; Chalupná P; Novotný A; Bortlík M; Krska Z; Lukás M
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):661-5. PubMed ID: 18600523
[TBL] [Abstract][Full Text] [Related]
12. Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases.
Schedel J; Gödde A; Schütz E; Bongartz TA; Lang B; Schölmerich J; Müller-Ladner U
Ann N Y Acad Sci; 2006 Jun; 1069():477-91. PubMed ID: 16855176
[TBL] [Abstract][Full Text] [Related]
13. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Cao Q; Zhu Q; Shang Y; Gao M; Si J
Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age.
de Boer NK; van Bodegraven AA; de Graaf P; van der Hulst RW; Zoetekouw L; van Kuilenburg AB
Ther Drug Monit; 2008 Jun; 30(3):390-3. PubMed ID: 18520612
[TBL] [Abstract][Full Text] [Related]
16. Severe azathioprine-induced myelotoxicity in a kidney transplant patient with thiopurine S-methyltransferase-deficient genotype (TPMT*3A/*3C).
Kurzawski M; Dziewanowski K; Ciechanowski K; Droździk M
Transpl Int; 2005 May; 18(5):623-5. PubMed ID: 15819814
[No Abstract] [Full Text] [Related]
17. Review article: thiopurines in inflammatory bowel disease.
Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
[TBL] [Abstract][Full Text] [Related]
18. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia after one month of azathioprine therapy in a Crohn's disease patient.
Kallel L; Naijaa N; Fekih M; Frikha I; Boubaker J; Bellaaj H; Romdhane NB; Filali A
J Clin Gastroenterol; 2010 Oct; 44(9):660. PubMed ID: 20216428
[No Abstract] [Full Text] [Related]
20. A case of therapy-related myeloid neoplasm in a patient with Crohn's disease treated with azathioprine.
Mullier F; Rahier JF; Maignen F; Cornet Y; Graux C; Chatelain C; Chatelain B; Dogne JM
Acta Haematol; 2012; 128(1):1-6. PubMed ID: 22572218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
